Successful trial on patients using new stem cell based treatment for wet age-related macular degeneration (AMD).
Results from a clinical study suggest the treatment is safe and effective.
The study is a major milestone for the London Project to Cure
Blindness and could lead to an ‘off-the-shelf’ treatment within five
The first patients to receive a new treatment derived from stem cells
for people with wet age-related macular degeneration (AMD) have
regained reading vision.
The results of this ground-breaking clinical study, published in Nature Biotech, described
the implantation of a specially engineered patch of retinal pigment
epithelium cells derived from stem cells to treat people with sudden
severe sight loss from wet AMD. It is hoped that it will also help treat
dry AMD in the future.
It’s the first description of a complete engineered tissue that has been successfully used in this way.
The study is a major milestone for the London Project to Cure
Blindness, a partnership between Professor Pete Coffey from University
College London and Professor Lyndon da Cruz, a retinal surgeon at
Moorfields Eye Hospital NHS Foundation Trust. The Project has also been
supported by the UCL Institute of Ophthalmology and the National
Institute for Health Research (NIHR).
AMD is the most common cause of sight loss in the UK, and can lead to
a rapid loss of central (reading) vision. The two patients who
underwent the procedure, a woman in her early 60s and a man in his 80s,
had the severe form of the condition (wet AMD) and declining vision.
The study investigated whether the diseased cells at the back the
patients’ affected eye could be replenished using the stem cell based
patch. A specially engineered surgical tool was used to insert the patch
under the retina in the affected eye of each patient in an operation
lasting one to two hours.
The patients were monitored for 12 months and reported improvements
to their vision. They went from not being able to read at all even with
glasses, to reading 60-80 words per minute with normal reading glasses.
Douglas Waters, 86, from Croydon, London, was one of two people who had
received the treatment at Moorfields Eye Hospital. He developed severe
wet AMD in July 2015 and received the treatment three months later in
his right eye.
He says: “In the months before the operation my sight was really poor
and I couldn’t see anything out of my right eye. I was struggling to
see things clearly, even when up-close. After the surgery my eyesight
improved to the point where I can now read the newspaper and help my
wife out with the gardening. It’s brilliant what the team have done and I
feel so lucky to have been given my sight back.”
Professor Lyndon da Cruz, consultant retinal surgeon at Moorfields Eye Hospital NHS Foundation Trust said:
“The results suggest that this new therapeutic approach is safe and
provides good visual outcomes. The patients who received the treatment
had very severe AMD, and their improved vision will go some way towards
enhancing their quality of life. We recognise that this is a small group
of patients, but we hope that what we have learned from this study will
benefit many more in the future.”
Professor Pete Coffey, UCL Institute of Ophthalmology said:
“This study represents real progress in regenerative medicine and
opens the door to new treatment options for people with age-related
macular degeneration. We hope this will lead to an affordable
‘off-the-shelf’ therapy that could be made available to NHS patients
within the next five years.”
Notes to editors
For more information or to speak to the researchers involved, please contact the Moorfields Eye Hospital press office.
For out of hours enquiries please call 020 7253 3411 to speak to the on call press officer.
‘Phase 1 clinical study of an embryonic stem cell–derived retinal
pigment epithelium patch in age-related macular degeneration,’ will be
published in Nature Biotech and is under a strict embargo until Monday 19 March 2018, 16:00 UK time / 12:00 US Eastern Time.
The paper can be accessed from 16:00 on 19 March via http://dx.doi.org/. The DOI is 10.1038/nbt.4114
How the procedure works
The retina is made of many different layers. One of the critical
layers, called the retinal pigment epithelium (RPE) separates blood
vessels from the nerve layer and nourishes the retina. This layer is
damaged in patients with AMD.
In this new approach, researchers took a stem cell – which is a
single cell – and reproduced it many times, turning them into a perfect
copy of the RPE layer that needs to be replaced in patients with AMD.
This is then placed onto a patch and inserted under the retina to
replace the damaged cells.
Age-related macular degeneration (AMD)
is the most common cause of sight loss in the developed world. More
than 600,000 people are affected by AMD in the UK. (Macular Society). It
usually affects people over the age of 60. There are two types of AMD,
wet and dry.
Wet AMD develops when abnormal blood vessels grow into the macula.
These leak blood or fluid which leads to vision loss and secondary
scarring of the macula and in some cases, rapid loss of central
(reading) vision. There is no cure for wet AMD, but it can be treated by
injecting drugs into the eye to stop the growth of the abnormal blood
vessels. These injections are needed regularly to preserve vision.
Dry AMD is the most common type of macular degeneration and affects
90% of the people who have the condition. In the dry form, there is a
breakdown or thinning of the layer of retinal pigment epithelial cells
(RPE) in the macula. These RPE cells support the light sensitive
photoreceptor cells that are so critical to vision. There is no
treatment at present for dry AMD after the photoreceptors are lost.
The London Project to Cure Blindness is
collaboration between Professor Pete Coffey from University College
London and Professor Lyndon da Cruz, a retinal Surgeon at Moorfields Eye
Hospital. The project aims to bring stem cell therapy for retinal
diseases, especially for age-related macular degeneration (AMD), to the
clinic as rapidly as possible. We believe stem cell based therapies for
these conditions have the greatest chances of preventing blindness,
restoring sight and improving sufferers’ quality of life in the future.
The London Project to Cure Blindness was established by a philanthropic
donation from an anonymous American donor. Philanthropy plays a
significant role in funding the programme, including continued support
from Moorfields Eye Charity.
The London Project to Cure Blindness acknowledges support from:
An anonymous philanthropic American donor, The Lincy Foundation USA,
Moorfields Eye Charity, NIHR Biomedical Research Centre at Moorfields
and the UCL Institute of Ophthalmology, The Macular Society, The UK
Medical Research Council (MRC), Cells for Sight manufacturing facility
at the UCL Institute of Ophthalmology and Moorfields, Pfizer Inc, CIRM
Moorfields Eye Hospital NHS Foundation Trust is a
world-leading provider of eye care services in the UK. We provide a wide
range of clinical services, caring for patients in over 30 locations in
and around London to provide expert treatment closer to patients’
homes. We also operate commercial divisions that provide care to private
patients in both London and the Middle East. With our academic partner,
the UCL Institute of Ophthalmology, we are recognised as a leading
centre of excellence in eye research and education. To find out more go
UCL Institute of Ophthalmology is one of a number of
specialised biomedical research centres within UCL. We conduct
cutting-edge science, attracting research workers of the highest
international calibre. In recognition of the Institute’s international
standing, the most recent HEFCE (Higher Education Funding Council for
England) Research Evaluation Framework exercise confirmed the
outstanding quality of research carried out at the Institute. According
to the 2017 Centre for World University Rankings, UCL is the best place
in the world to study ophthalmology. For further information go to: https://www.ucl.ac.uk/ioo/
The National Institute for Health Research (NIHR) Moorfields Biomedical Research Centre (BRC) was established in April 2007 and awarded its third five-year term by the NIHR in April 2017. Alongside the NIHR Moorfields Clinical Research Facility (CRF) for Experimental Medicine, our mainpurpose
is to accelerate the progress of biomedical research from the
laboratory into early phase safety trials so that scientific
breakthroughs that hold promise for patients can proceed along the
clinical testing pathway more quickly. Our BRC is one of 20 Biomedical
Research Centres awarded to NHS/university partnerships with an
outstanding international reputation for research. As a partnership
between Moorfields Eye Hospital and UCL Institute of Ophthalmology we
are at the centre of one of the largest ophthalmic research sites in the
world. For more information go to: www.brcophthalmology.org
The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research.
Established by the Department of Health and Social Care, the NIHR:
funds high quality research to improve health
trains and supports health researchers
provides world-class research facilities
works with the life sciences industry and charities to benefit all
Moorfields Eye Charity supports the work of
Moorfields Eye Hospital and its research partner, the UCL Institute of
Ophthalmology, making a difference for patients at the hospital and for
people with sight problems around the world. It provides grants and
raises money to help the hospital provide the best possible care for its
patients, educate the researchers and clinicians of tomorrow and
support leading-edge research that aims to develop new treatments for
blinding diseases. To find out more go to: www.moorfieldseyecharity.org.uk
2022 Wilmer Annual Report
The eye, which is more easily accessible than organs shielded by skin and muscle, often reveals insights into a patient’s overall state of health. The Wilmer Eye Institute’s Annual Report details stories of lifesaving discoveries, innovative educational initiatives, and groundbreaking research that are advancing patient care and the field of ophthalmology. Read the report: https://www.hopkinsmedicine.org/news/publications/wilmer_issues/annual-report-2022
REMINDER: Call for Projects Interested in funding for a project? The WAEH can finance two to three projects per year with 7.500,- euro. You can use the following WAEH project format to send in your project proposal: WAEH project proposal.Round 1 – Deadline 31 January 2023– Incoming proposals reviewed by board in February / March board meeting– […]
Longitudinal Use of Telehealth During the COVID-19 Pandemic and Utility of Asynchronous Testing for Subspecialty-Level Ophthalmic Care
Publication by WAEH Member UCSF – Department of Ophthalmology Importance: Telehealth in ophthalmology has traditionally focused on preventive disease screening with limited use in outpatient evaluation. The unique conditions of the COVID-19 pandemic afforded the opportunity to evaluate different implementations of teleophthalmology at scale, providing insight into expanding teleophthalmology care. Objective: To compare telehealth use in ophthalmology […]
The Victoria Cohen Scholarship 2023/24 – open for applications
The Victoria Cohen Scholarship is now open for applications from aspiring ocular oncologists in need of financial support throughout their fellowship. The Victoria Cohen Eye Cancer Charitable Trust was established in 2021 in memory of the late Victoria Cohen, former president of ISOO. Victoria was always keen to support the next generation of eye surgeons […]
Eye cancer is a terrible disease and there are not enough ocular oncologists in the world. Training takes time and money. The Victoria Cohen Eye Cancer Charitable Trust provides scholarships to support aspiring ocular oncologists through their training and education. The deadline for applications for the Victoria Cohen Scholarship 2023/24 is the 31st March 2023. For […]